“Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”, J of Skin, vol. 7, no. 6, p. s243, Nov. 2023, doi: 10.25251/skin.7.supp.243.